ELIDEL

LOE Approaching

pimecrolimus

NDATOPICALCREAM
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Calcineurin Inhibitors

Pharmacologic Class:

Calcineurin Inhibitor Immunosuppressant

Indications (1)

Clinical Trials (5)

NCT00946478N/ACompleted

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Started Oct 2009
40 enrolled
Atopic Dermatitis
NCT00403559Phase 2Completed

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Started May 2007
113 enrolled
Seborrheic Dermatitis
NCT00507832Phase 2Completed

Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease

Started Apr 2007
30 enrolled
Prurigo Nodularis
NCT00810862Phase 4Terminated

Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Started Nov 2006
18 enrolled
Atopic Dermatitis
NCT00393263Phase 2Completed

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

Started Oct 2006
38 enrolled
Lichen Sclerosus